GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis India Ltd (BOM:500672) » Definitions » Cyclically Adjusted PB Ratio

Novartis India (BOM:500672) Cyclically Adjusted PB Ratio : 2.65 (As of Sep. 22, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Novartis India Cyclically Adjusted PB Ratio?

As of today (2024-09-22), Novartis India's current share price is ₹1052.50. Novartis India's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was ₹397.20. Novartis India's Cyclically Adjusted PB Ratio for today is 2.65.

The historical rank and industry rank for Novartis India's Cyclically Adjusted PB Ratio or its related term are showing as below:

BOM:500672' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.41   Med: 1.75   Max: 2.96
Current: 2.65

During the past years, Novartis India's highest Cyclically Adjusted PB Ratio was 2.96. The lowest was 1.41. And the median was 1.75.

BOM:500672's Cyclically Adjusted PB Ratio is ranked worse than
66.96% of 569 companies
in the Drug Manufacturers industry
Industry Median: 1.77 vs BOM:500672: 2.65

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novartis India's adjusted book value per share data for the three months ended in Mar. 2024 was ₹301.659. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₹397.20 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novartis India Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Novartis India's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis India Cyclically Adjusted PB Ratio Chart

Novartis India Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.41 1.49 1.41 2.59

Novartis India Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.41 - 1.78 - 2.59

Competitive Comparison of Novartis India's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Novartis India's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis India's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis India's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novartis India's Cyclically Adjusted PB Ratio falls into.



Novartis India Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Novartis India's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1052.50/397.2
=2.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis India's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Novartis India's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=301.659/153.0345*153.0345
=301.659

Current CPI (Mar. 2024) = 153.0345.

Novartis India Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 94.103 0.000
201409 309.661 96.780 489.653
201412 0.000 96.780 0.000
201503 323.252 97.163 509.132
201506 0.000 99.841 0.000
201509 350.198 101.753 526.689
201512 0.000 102.901 0.000
201603 373.451 102.518 557.470
201606 0.000 105.961 0.000
201609 321.331 105.961 464.083
201612 0.000 105.196 0.000
201703 326.800 105.196 475.414
201706 0.000 107.109 0.000
201709 327.723 109.021 460.028
201712 0.000 109.404 0.000
201803 297.131 109.786 414.180
201806 0.000 111.317 0.000
201809 294.041 115.142 390.808
201812 0.000 115.142 0.000
201903 307.479 118.202 398.088
201906 0.000 120.880 0.000
201909 293.385 123.175 364.506
201912 0.000 126.235 0.000
202003 291.902 124.705 358.214
202006 0.000 127.000 0.000
202009 287.014 130.118 337.563
202012 0.000 130.889 0.000
202103 288.038 131.771 334.519
202106 0.000 134.084 0.000
202109 285.750 135.847 321.903
202112 0.000 138.161 0.000
202203 280.145 138.822 308.826
202206 0.000 142.347 0.000
202209 299.188 144.661 316.506
202212 0.000 145.763 0.000
202303 314.149 146.865 327.347
202306 0.000 150.280 0.000
202309 284.430 151.492 287.326
202312 0.000 152.924 0.000
202403 301.659 153.035 301.659

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novartis India  (BOM:500672) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Novartis India Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Novartis India's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis India Business Description

Traded in Other Exchanges
N/A
Address
Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company single business segment namely Pharmaceuticals, Its Pharmaceutical business focuses on Bone and Pain, Calcium portfolio, Gynecology, and Neurosciences.

Novartis India Headlines

No Headlines